期刊文献+

瑞舒伐他汀合成路线图解 被引量:4

Graphical Synthetic Routes of Rosuvastatin
下载PDF
导出
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2005年第9期585-587,共3页 Chinese Journal of Pharmaceuticals
  • 相关文献

参考文献15

  • 1侯立飞.降血脂药罗舒伐他汀[J].药学进展,2004,28(1):48-49. 被引量:6
  • 2封宇飞,雷静,吕俊玲,孙春华.新型降酯药——罗伐他汀[J].中国临床药理学杂志,2004,20(3):234-236. 被引量:2
  • 3Quirk J, Thornton M, Kirkpatrick P. Rosuvastatin calcium [J]. Nat Rev Drug Discov, 2003, 2 (10): 769-770.
  • 4Carswell CI, Plosker GL, Jarvis B. Josuvastatin [J]. Drugs,2002, 62 (14): 2075-2085.
  • 5Matsushita A, Oda M, Kawachi Y, et al. Preparation of aminopyrimidine compounds [P]. WO: 2003006439, 2003-01-23. (CA 2003, 138: 122651)
  • 6Hirai K, Ishiba T, Koike H, et al. Pyrimidine derivatives [P].US: 5260440, 1993-11-09. (CA 1993, 118: 254949)
  • 7Kumar Y, De S, Rafeeq M, et al. Process for the preparation of rosuvastatin[P]. WO: 2003097614, 2003-11-27. (CA 2003, 139: 395947)
  • 8Horbury J, Taylor NP. Process for preparing the calcium salt of rosuvastatin[P]. WO: 2004014872, 2004-02-19. (CA 2004, 140: 187485)
  • 9Niddam-Hildesheim V, Lifshitz-Liron R, Lidor-Hadas R. Processes for preparing calcium salt forms of statins [P]. WO:2003016317, 2003-02-27. (CA 2003, 138: 204870)
  • 10Crabb JN, Horbury J, Taylor NP. Improved production of rosuvastatin calcium salt[P]. WO: 2004108691, 2004-12-16. (CA 2005, 142: 56338)

二级参考文献4

  • 1Masamichi Watanabe,Haruo Koike,Teruyuki Ishiba,et al.Synthesis and biological activity of methanesulfonamide pyrimidine-and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates,a novel series of HMG-CoA reductase inhibitors[J].Bioorg Med Chem
  • 2Kentaro Hiral,Teruyuki Ishiba,Haruo Koike,et al.Pyrimidine derivative[P].US:5260440,1993-11-09.
  • 3Rolf Angerbauer,Peter Fey,Walter Hübsch.7-(Polysubstituted pyridyl)-rept-6-endates useful for treting hyperproteinaemia lipoproteinaemia or arteriosclerosis[P].US:5169857,1992-12-08.
  • 4K. Cooper,P. Martin,A. Dane,M. Warwick,D. Schneck,M. Cantarini. The effect of fluconazole on the pharmacokinetics of rosuvastatin[J] 2002,European Journal of Clinical Pharmacology(8):527~531

共引文献7

同被引文献51

  • 1丁德荣,沈竞康.ACAT抑制剂的研究进展[J].中国新药杂志,2005,14(4):396-400. 被引量:3
  • 2何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:31
  • 3蔡伟,张国英,赵文镜,罗永慧.瑞舒伐他汀钙的合成[J].江苏药学与临床研究,2005,13(4):9-10. 被引量:9
  • 4邵飞,孙笑宾,魏启华.瑞舒伐他汀中间体的合成工艺改进[J].精细化工,2006,23(2):192-194. 被引量:6
  • 5黄伟,岑均达.Ezetimibe的合成[J].中国医药工业杂志,2006,37(6):364-366. 被引量:16
  • 6De D,Khanna I.Recent trends in HDL modulating therapies[J].Ann Rep in Med Chem,2007,42:177-191.
  • 7Ashen MD,Blumenthal RS.Low HDL cholesterol levels[J].N EngJ Med,2005,353 (12):1252-1260.
  • 8Pfefferkorn JA,Song Y,Sun KL,et al.Design and synthesis of hepatoselective,pyrrole-based HMG-CoA reduetase inhibitors[J].Bioorg Med Chem Lett,2007,17:4538-4544.
  • 9Bratton LD,Auerbach B,Choi C,et al.Discovery of pyrrole based hepatoselective ligands as potent inhibitors of HMGCoA reductase[J].Bioorg Med Chem,2007,15:5576-5589.
  • 10Pfefferkom JA,Choi C,Larsen SD,et al.Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors:Discovery of (3R,5R) -7-[2-(4-fluoro-phenyl) -4-isopropyl 5-(4-methyl-benzylcarbamoyl) -2H-pyrazol-3-yl] -3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia[J].J Med Chem,2008,51(1):31-45.

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部